Madlen Marx

GD2 targeting by dinutuximab beta is a promising immunotherapeutic approach against malignant glioma

Sascha Marx, Fabian Wilken, Isabel Viola Wagner et al. · Journal of Neuro-Oncology · 2020 · 24 citations

Medicine, Immunology, Oncology +14

Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial

Nikolai Siebert, Sascha Troschke‐Meurer, Madlen Marx et al. · Cancers · 2018 · 21 citations · Full text

Pharmacy, Immunology, Pharmacokinetics +13

Low CD4⁺/CD25⁺/CD127⁻ regulatory T cell- and high INF-γ levels are associated with improved survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2

Sascha Troschke‐Meurer, Nikolai Siebert, Madlen Marx et al. · OncoImmunology · 2019 · 20 citations · Full text

Life Sciences, Immunology, Oncology +17

Platelet activation parameters and platelet-leucocyte-conjugate formation in glioblastoma multiforme patients

Sascha Marx, Maximilian Splittstöhser, Frederik Kinnen et al. · Oncotarget · 2018 · 16 citations · Full text

Medicine, Oncology, Pharmacology +9

Report on a molecular diagnostic service for familial hypercholesterolemia in Afrikaners.

Maritha J. Kotze, E. Langenhoven, Leonora Theart et al. · PubMed · 1994 · 11 citations

Life Sciences, Genetics, Molecular Genetics +17